shutterstock_1873015870_alpha_tauri_3d_graphics

Alpha Tauri 3D Graphics / Shutterstock.com

23 August 2022FeaturesBiotechnologyIne Vanderleyden

Microbial consortia and IP in Europe

Our body hosts trillions of microorganisms that live symbiotically on and within the human body. This ‘microbiome’ is essential to our health and microbial imbalance or dysbiosis increases the susceptibility to many diseases, including inflammatory bowel disease (IBD), liver disease, atherosclerosis, and other severe pathologies. Given its central role in health and disease, the microbiome has become a prominent therapeutic target.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Will Big Pharma get the bug for microbiome therapies?

6 May 2020 The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.

Biotechnology

Patenting livestock microbiome tech: trends and takeaways

27 October 2022 Developments in microbiome tech are aimed at reducing the need for antibiotics in livestock farming and have led to some notable patenting trends and requirements, explains Rosie McDowell of EIP.

More on this story

Will Big Pharma get the bug for microbiome therapies?

6 May 2020 The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.

Biotechnology

Patenting livestock microbiome tech: trends and takeaways

27 October 2022 Developments in microbiome tech are aimed at reducing the need for antibiotics in livestock farming and have led to some notable patenting trends and requirements, explains Rosie McDowell of EIP.

More on this story

Will Big Pharma get the bug for microbiome therapies?

6 May 2020 The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.

Biotechnology

Patenting livestock microbiome tech: trends and takeaways

27 October 2022 Developments in microbiome tech are aimed at reducing the need for antibiotics in livestock farming and have led to some notable patenting trends and requirements, explains Rosie McDowell of EIP.

More features

Sandoz wins $137.2m payout for lost profits in generic launch

Dexcom suffers second patent revocation at hands of UPC

Sanofi signs global rights deal to develop rare cancer therapy

Does the UPC offer a fresh take on patent validity?

Litigation implications of the USPTO’s terminal disclaimer proposal

Ipsen files further suit against CSPC over pancreatic cancer drug generic

Federal Circuit denies rehearing in heart valve case

Technical prejudice in support of inventive step: A double-edged sword?